Certara, model-informed drug development and regulatory science company, has acquired a data visualisation software as a service (SaaS) company, BaseCase Management, strengthening the company’s visualisation and communications capabilities across its data science decision-support value chain.
Partnership
“We are delighted that BaseCase is joining Certara and we are looking forward to expanding the applications for its user-friendly, mobile communications technology. BaseCase simplifies communication of complex data and models,” said Thomas Kerbusch, PhD, president of Certara Strategic Consulting Services. “BaseCase’s interactive platform will enable pharmaceutical and medical technology companies to visualize model results and large, real-world datasets to make sound decisions quickly, within controlled communication cascades.”
“The BaseCase team is excited to join Certara and take adoption of our visualisation and communications platform to the next level. We are confident that we are a great match,” remarked BaseCase CEO Gijs Hubben, PhD. “Both companies have comparable cultures — entrepreneurial, dynamic, diverse and quality driven — and possess a similar mix of scientific and software engineering staff. With the growing acceptance of modelling and simulation in life sciences, comes the need to simplify complex data science concepts and results. Certara is the perfect home for BaseCase.”
“Certara’s extensive software development capability and deep expertise in model-informed drug development will enable us to further accelerate BaseCase’s evolution and growth in this expanding market space,” added BaseCase CTO, Diarmuid Glynn. “We have already identified several expansion projects that will result from the merger.”
Financial details about the transaction were not disclosed.
